The company has a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications, enabling medical companies to provide satisfactory treatment options. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options.